Cargando…

Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization

BACKGROUND: We previously reported a PI3K inhibitor S14161 which displays a promising preclinical activity against multiple myeloma (MM) and leukemia, but the chiral structure and poor solubility prevent its further application. METHODS: Six S14161 analogs were designed based on the structure–activi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Kunkun, Xu, Xin, Chen, Guodong, Zeng, Yuanying, Zhu, Jingyu, Du, Xiaolin, Zhang, Zubin, Cao, Biyin, Liu, Zhaopeng, Mao, Xinliang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3924225/ https://www.ncbi.nlm.nih.gov/pubmed/24428908 http://dx.doi.org/10.1186/1756-8722-7-9

Ejemplares similares

A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma
por: Zhu, Jingyu, et al.
Publicado: (2014)

Correction: A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma
por: Zhu, Jingyu, et al.
Publicado: (2019)

An inhibitor of cholesterol absorption displays anti-myeloma activity by targeting the JAK2-STAT3 signaling pathway
por: Xu, Xin, et al.
Publicado: (2016)

SC06, a novel small molecule compound, displays preclinical activity against multiple myeloma by disrupting the mTOR signaling pathway
por: Han, Kunkun, et al.
Publicado: (2015)

Ring finger protein 6 promotes breast cancer cell proliferation by stabilizing estrogen receptor alpha
por: Zeng, Yuanying, et al.
Publicado: (2017)

Inhibition of the deubiquitinase USP5 leads to c-Maf protein degradation and myeloma cell apoptosis
por: Wang, Siyu, et al.
Publicado: (2017)

Clioquinol induces pro-death autophagy in leukemia and myeloma cells by disrupting the mTOR signaling pathway
por: Cao, Biyin, et al.
Publicado: (2014)

The ubiquitin-conjugating enzyme UBE2O modulates c-Maf stability and induces myeloma cell apoptosis
por: Xu, Yujia, et al.
Publicado: (2017)

A novel small molecule agent displays potent anti-myeloma activity by inhibiting the JAK2-STAT3 signaling pathway
por: Zhang, Zubin, et al.
Publicado: (2016)

Correction: A novel small molecule agent displays potent anti-myeloma activity by inhibiting the JAK2-STAT3 signaling pathway
por: Zhang, Zubin, et al.
Publicado: (2016)

Anti-bacterial and anti-viral nanchangmycin displays anti-myeloma activity by targeting Otub1 and c-Maf
por: Xu, Yujia, et al.
Publicado: (2020)

The deubiquitinase USP10 restores PTEN activity and inhibits non–small cell lung cancer cell proliferation
por: He, Yuanming, et al.
Publicado: (2021)

Inhibition of the Otub1/c-Maf axis by the herbal acevaltrate induces myeloma cell apoptosis
por: Sun, Tong, et al.
Publicado: (2021)

The ubiquitin ligase HERC4 suppresses MafA transcriptional activity triggered by GSK3β in myeloma by atypical K63-linked polyubiquitination
por: Zhang, Zubin, et al.
Publicado: (2023)

A virtual screen identified C96 as a novel inhibitor of phosphatidylinositol 3-kinase that displays potent preclinical activity against multiple myeloma in vitro and in vivo
por: Tang, Juan, et al.
Publicado: (2014)

Interferon-stimulated gene 15 induces cancer cell death by suppressing the NF-κB signaling pathway
por: Mao, Hongwu, et al.
Publicado: (2016)

Induction of zinc finger protein RNF6 auto-ubiquitination for the treatment of myeloma and chronic myeloid leukemia
por: Zhuang, Haixia, et al.
Publicado: (2022)

The Natural Pesticide Dihydrorotenone Induces Human Plasma Cell Apoptosis by Triggering Endoplasmic Reticulum Stress and Activating p38 Signaling Pathway
por: Zhang, Jieyu, et al.
Publicado: (2013)

Correction: The Natural Pesticide Dihydrorotenone Induces Human Plasma Cell Apoptosis by Triggering Endoplasmic Reticulum Stress and Activating p38 Signaling Pathway
por: Zhang, Jieyu, et al.
Publicado: (2020)

PI3k Inhibitors in NHL and CLL: An Unfulfilled Promise
por: Bou Zeid, Naji, et al.
Publicado: (2023)

Saponins From Paris forrestii (Takht.) H. Li Display Potent Activity Against Acute Myeloid Leukemia by Suppressing the RNF6/AKT/mTOR Signaling Pathway
por: Lu, Qin, et al.
Publicado: (2018)

Suppression of USP7 induces BCR-ABL degradation and chronic myelogenous leukemia cell apoptosis
por: Jiang, Shuoyi, et al.
Publicado: (2021)

Design, Synthesis, and Biological Evaluation of Novel Thienopyrimidine Derivatives as PI3Kα Inhibitors
por: Yu, Lide, et al.
Publicado: (2019)

Checkpoint inhibitors and myeloma: promises, deadlocks and new directions
por: Bertamini, Luca, et al.
Publicado: (2020)

Modulation of Platelet Activation and Thrombus Formation Using a Pan-PI3K Inhibitor S14161
por: Yi, Wenxiu, et al.
Publicado: (2014)

Checkpoint Inhibitors in Multiple Myeloma: Intriguing Potential and Unfulfilled Promises
por: Alkharabsheh, Omar, et al.
Publicado: (2021)

PI3K inhibitor treatment ameliorates the glucocorticoid insensitivity of PBMCs in severe asthma
por: Bi, Jing, et al.
Publicado: (2020)

The PI3K inhibitor GDC-0941 displays promising in vitro and in vivo efficacy for targeted medulloblastoma therapy
por: Ehrhardt, Michael, et al.
Publicado: (2014)

Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
por: Jayaweera, Shansa Pranami E., et al.
Publicado: (2021)

Discovery of a novel phosphoinositide 3-kinase gamma (PI3Kγ) inhibitor against hematologic malignancies and theoretical studies on its PI3Kγ-specific binding mechanisms
por: Zhu, Jingyu, et al.
Publicado: (2019)

A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo
por: Glauer, J, et al.
Publicado: (2013)

LY294002 Is a Promising Inhibitor to Overcome Sorafenib Resistance in FLT3-ITD Mutant AML Cells by Interfering With PI3K/Akt Signaling Pathway
por: Huang, Amin, et al.
Publicado: (2021)

Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma
por: Oliva, Stefania, et al.
Publicado: (2018)

Immunotherapy of Multiple Myeloma: Promise and Challenges
por: Abramson, Hanley N
Publicado: (2021)

AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma
por: Gu, Chunyan, et al.
Publicado: (2022)

Selection Study for B+- -> (K-+ pi+- pi-+ pi+-)D K+- and B+- -> (K+ K- pi+ pi-)D K+-".
por: Hunt, P, et al.
Publicado: (2009)

PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment
por: Piddock, R E, et al.
Publicado: (2017)

Combined Treatment with PI3K Inhibitors BYL-719 and CAL-101 Is a Promising Antiproliferative Strategy in Human Rhabdomyosarcoma Cells
por: Piazzi, Manuela, et al.
Publicado: (2022)

The investigation of $K^+\pi^−, \pi^+K^−$ and $\pi^+\pi^−$ atoms
por: Yazkov, Valeriy
Publicado: (2016)

Natural Polyketides Act as Promising Antifungal Agents
por: Wang, Li, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rc4ggmcggv10qv784cqsg87gjk